In situ cervical carcinoma incidence statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of in situ cervical carcinoma, 2015-2017, UK.

 

Age

Peak rate of cervical cancer in situ cases, 2015-2017, UK

 

Trend over time

Change in cervical carcinoma in situ incidence rates since the early 1990s, Females, UK

 

Cervical carcinoma in situ incidence rates (European age-standardised (AS) rates) Open a glossary item for females are significantly higher than the UK average in Scotland and Northern Ireland, and similar to the UK average in all other UK constituent countries.

Cervical Carcinoma In Situ (D06), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, Females, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Cases 20,978 2,319 1,110 787 25,194
Crude Rate 74.6 83.3 70.0 82.8 75.3
AS Rate 72.4 82.3 74.8 81.2 73.5
AS Rate - 95% LCL 71.4 78.9 70.4 75.6 72.6
AS Rate - 95% UCL 73.4 85.6 79.2 86.9 74.4
Persons Cases 20,978 2,319 1,110 787 25,194
Crude Rate 37.7 42.7 35.5 42.1 38.1
AS Rate 36.1 41.7 37.4 41.1 36.7
AS Rate - 95% LCL 35.6 40.0 35.2 38.2 36.3
AS Rate - 95% UCL 36.6 43.4 39.6 44.0 37.2

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item  around the AS Rate Open a glossary item
 

Wales and Northern Ireland include all cases of in situ cervical carcinoma, whereas Scotland and England include only those which have been confirmed by a pathologist. This contributes to the differences seen between countries. Differences between countries may also reflect risk factor prevalence in years past.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 D06.

Last reviewed:

Cervical carcinoma in situ incidence is strongly related to age, with the highest incidence rates being in the 25 to 29 age group. In the UK in 2015-2017, on average each year less than 1% of new cases (0%) were in females aged 75 and over.[1-4] The highest incidence rates overall being in younger females - the converse pattern to most cancers.

Age-specific incidence rates rise sharply from around age 15-19 and peak in the 25-29 age group, then drop sharply. The highest rates are in the 25 to 29 age group.

Cervical carcinoma in situ (D06), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Females, UK, 2015-2017

For cervical carcinoma in situ, most cases are identified through the cervical screening programme. Incidence increases rapidly when routine screening starts at age 25, then falls until routine screening ends at age 64, with very low rates thereafter. This reflects the diagnosis of prevalent cases at first-time screening, and the likely peak of HPV exposure in early adulthood.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, D06.

Last reviewed:

Cervical carcinoma in situ European age-standardised (AS) Open a glossary item incidence rates for females increased by 12% in the UK between 1993-1995 and 2015-2017.[1-4].

Over the last decade in the UK (between 2005-2007 and 2015-2017), cervical carcinoma in situ AS incidence rates for females remained stable.[1-4]

Cervical Carcinoma In Situ (ICD-10 D06), European Age-Standardised Incidence Rates, Females, UK, 1993-2017

Cervical carcinoma in situ incidence rates have decreased overall in most broad age groups in females in the UK since the early 1990s, but have increased in some.[1-4] Rates in 0-24s have decreased by 39%, in 25-34s have increased by 55%, in 35-49s have decreased by 4%, in 50-64s have decreased by 33%, in 65-79s have decreased by 67%, and in 80+s have decreased by 55%.

Cervical Carcinoma In Situ (ICD-10 D06), European Age-Standardised Incidence Rates, By Age, Females, UK, 1993-2017

Cervical carcinoma in situ incidence trends probably reflect the effective implementation of the UK cervical screening programmes in the late 1980s – most cases are identified through the screening programme.[5] Changing prevalence of risk factors probably also plays a part, particularly among younger women in more recent years.[5]

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  5. Pesola F and Sasieni P. Impact of screening on cervical cancer incidence in England: a time trend analysis. BMJ 2019; 9(1) e026292.

About this data

Data is for UK, 1993-2017, ICD-10 D06.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.